NCT01963715View on ClinicalTrials.gov

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
EGFR Positive Solid Tumors
Interventions
DRUG

IMGN289

Trial Locations (4)

21287

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

48201

Karmanos Cancer Institute, Detroit

90048

Cedars-Sinai Medical Center, Los Angeles

02215

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

ImmunoGen, Inc.
All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY